Author: Editor

@OncEd Presents Dr. Claire Temple-Oberle – Interleukin-2 for In transit Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Jeff Sosman – Treatment of Non-BRAFV600E Melanoma With Targeted Therapy – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Merrick Ross – Intralesional Therapy For Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Merrick I. Ross – The Role of Neo-Adjuvant Therapy In Resectable Advanced Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Lynne Robertson – Population Screening For Melanoma – An Alberta Trial – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Jason Rivers – Diagnostic Advances In Melanoma Detection – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Dayna Miyashiro – Immunotherapy In Stage III Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Iren Kossintseva – Melanoma Inflammatory Response Signature – Canadian Melanoma Conference 2015

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton, UK, discusses the challenges to adherence to oral cancer therapies, as well as the role of a multidisciplinary team approach for optimising safety and adherence. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. David Hogg – Managing The Advanced Non-Melanoma Skin Cancers – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Omid Hamid – PD1 Therapy and Biomarkers for Response – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Axel Hauschild – Adjuvant Melanoma Treatment: Past, Present and Future – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Femida Gwadry-Sridhar – Do We Really Need Big Data – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Michael Davies – Clinical & Therapeutic Significance of the PI3K-AKT Pathway in Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Joel Claveau & Dr. Scott Ernst – A Practical Multi-Disciplinary Discussion of Challenging Cases in Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Boris Bastian – Towards an Integrated Taxonomy of Melanocytic Neoplasms – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Eric Valli̬res РInnovation In Lung Cancer Surgery РCLCCO 2015

@OncEd Presents Dr. Glenwood Goss – Welcome From NCIC – CLCCO 2015

@OncEd Presents Dr. Sunil Verma – A National Strategy On Molecular Testing In NSCLC – CLCCO 2015

@OncEd Presents Dr. Yee Ung – A Canadian Radiation Oncologist Perspective – CLCCO 2015

@OncEd Presents Dr. Martin Reck – Lung Cancer: Today and Tomorrow – CLCCO 2015

@OncEd Presents Dr. Natasha Leigh – Third Generation EGFR TKI – CLCCO 2015

@OncEd Presents Dr. Gary Lee – Management of Malignant Pleural Effusions – CLCCO 2015

@OncEd Presents Dr. Rosalyn Juergens – Immunotherapy In NSCLC – CLCCO 2015

@OncEd Presents Dr. Laurie Gaspar – Lung Cancer Today: Maximizing the Therapeutic Ratio – CLCCO 2015

@OncEd Presents Dr. Krista Noonan – Debate: TKI in Adjuvant Setting For EGFR +VE Patients – No – CLCCO 2015

@OncEd Presents Dr. Jason Agulnik – Debate: TKI in Adjuvant Setting For EGFR +VE Patiens – Yes – CLCCO 2015

@OncEd Presents Dr. Paris Ingledew – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – Yes – CLCCO 2015

@OncEd Presents Dr. Patrick Cheung – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – No – CLCCO 2015

@OncEd Presents Dr. Charles Butts – Debate: Targeted Therapy Vs. Immunotherapy For First Line In SNCLC – NO – CLCCO 2015

@OncEd Presents Dr. Normand Blais – Debate: Targeted Therapy VS. Immunotherapy For First Line In NSCLC – YES – CLCCO 2015

@OncEd Presents Dr. Ross Camidge – The Changing World of Alk Mutations and Treatment – Lung Cancer – CLCCO 2015

@OncEd Presents Dr. Robert Kerbel – Anti-Angiogenic Therapies In Cancer – 2015

@OncEd Presents Dr. Alexander Lyon – Proteasome Inhibition – GCOS 2015

@OncEd Presents Dr. Lee Jones – Impairments In Cardiovascular Reserve Capacity And Efficacy of Exercise Countermeasures In Cancer – GCOS 2015

@OncEd Presents Dr. Michael Fradley – QT Prolongation And Other Electrophysiologic Considerations In Cancer Patients Undergoing Stem Cell therapy – GCOS 2015

@OncEd Presents Dr. Giorgio Minotti – Developing a Dedicated Cardio-Oncology Journal – GCOS 2015

@OncEd Presents Dr. Zaza Iakobishvili – Can Cardio-Oncology Deliver Improved Practice Internationally – GCOS 2015

@OncEd Presents Dr.Susan Dent – Establishing a Cardio-Oncology Clinic – GCOS 2015

@OncEd Presents Dr. Paul Richardson – Contemporary Treatment of Multiple Myeloma – GCOS 2015

@OncEd Presents Dr. Daniela Cardinale – The Practical Use of Cardiac Biomarkers – GCOS 2015

@OncEd Presents Dr. Ronald Schwartz – Leading Lessons of Radionuclide Angiocardiography – GCOS 2015

@OncEd Presents Dr. Anju Nohria – Autonomic Dysfunction in Patients Treated With Mediastinal or Neck Radiation – GCOS 2015

@OncEd Presents Dr. Dinesh Thavendiranathan – The Use of Strain And Newer Echocardiography Imaging Techniques – GCOS 2015

@OncEd Presents Dr. Sebastian Szmit – Is Dasatinib-Related Pulmonary Hypertension a Concern – GCOS 2015

@OncEd Presents Dr. Michael Savona – A Revolution in the treatment of Leukemia – GCOS 2015

@OncEd Presents Dr. Kathleen Pritchard – Comprehensive Cancer Care Includes Addressing Potential Impact of Cardiovascular Toxicity – GCOS 2015

@OncEd Presents Dr. Stephen Chia & Dr. Hope Rugo – Controversies and Challenges in Management of Metastatic Breast Cancer – Breast Cancer – 2015

@OncEd Presents Dinner Symposium: Shaping the Standard of Care – Best of Lung Cancer – 2015

@OncEd Presents Dr. Ros Juergens – Lung Cancer Immunotherapy: The Landscape in Canada – Best of Lung Cancer 2015

@OncEd Presents Dr. Scott Laurie – Squamous Cell Lung Update – Best of Lung Cancer – 2015

@OncEd Presents Dr. Barb Melosky – New Targets in NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Case Based Discussions: Locally Advanced Lung Cancer – Best of Lung Cancer – 2015

@OncEd Presents Dr. Jeff Rothenstein – Advances in Alk-Positive NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Dr. Ron Burkes – Adjuvant Treatment In NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Dr. Heidi Roberts – Screening Update – Best of Lung Cancer – 2015

@OncEd Presents Lunch Symposium: Mapping Better Outcomes in Advanced NSCLC – Best Of Lung Cancer – 2015

@OncEd Presents Panel Discussion – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Neil Berinstein – The Future Of Immuno-Oncology – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Marcus Butler – T-Cell Transfer Therapies – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Omid Hamid – Immunotherapy For Melanoma Patients – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Natasha Leighl Immunotherapy in Lung Cancer – Best Of Immuno-Oncology 2015

@OncEd Presents Dr. Georg Bjarnason – Immuno-Oncology: Renal Cell – Best Of Immuno-Oncology 2015

@OncEd Presents Dr. Linh Nguyen – The Basic Premise of Immuno-Oncology – Best Of Immuno-Oncology

@OncEd Presents Panel Discussion: Workforce Planning in Oncology Across Canada – CAMO 2015

@OncEd Presents Dr. Jean Latreille – HR Planning in Oncology: Quebec – CAMO 2015

@OncEd Presents Dr. Leonard Kaizer – HR Planning in Oncology: Ontario – CAMO 2015

@OncEd Presents Dr. Chris Lee – HR Planning in Oncology: British Columbia – CAMO 2015

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of Warwick, Coventry, UK, discusses the clinical significance of chemotherapy-induced nausea and vomiting, which continues to greatly impact the quality of life of patients, and the role of oncology nurses in the management and education of patients undergoing potentially emetogenic therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit that was designed to evaluate the Acute Oncology Service nursing role across the London Cancer Alliance, which is a collaboration of 17 healthcare provider organisations in London, as well as determining their professional development needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

From our Ask the Expert series, MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance and the Fred Hutchinson Cancer Research Center responds to Patient Power community member Amandas question, Is there any research on pregnancy and essential thrombocythemia (ET)? What are my risks? Dr. Scott discusses both historical and anecdotal data, including safe treatments. Dr. Scott cautions patients, however, to be sure to consult an MPN expert both before and during pregnancy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our Ask the Expert series, MPN expert Dr. Jamile Shammo, with Rush University Medical Center in Chicago, answers a question from Jane, What does it mean if you are JAK+ or CALR+, and how does it affect my treatment or prognosis? Dr. Shammo compares and contrasts these two mutations, offering insight based on clinical studies and registry data. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There is now an increasingly large volume of data that supports that nutritional factors, not just diet but obesity and physical activity, that determine the body’s ability to fight cancer. After smoking, obesity and physical activity are the most important factors that can be used to prevent cancer.

@OncEd Presents Dr. Allan Covens – BRCA mutations in ovarian cancer

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects of Pomi-T on prostate-specific antigen (PSA) levels in prostate cancer patients. He highlights the main results, such as the reduction of PSA levels, and other important factors that should be considered when taking food supplements.

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert Thomas suggests changes in lifestyle, such as daily light exercise and a healthy and balanced diet.

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas suggests that cancer patients and the general community, should increase the intake of fruit and vegetables, rich in polyphenols. he then goes on to discuss the results of a double-blind, randomised clinical trial (Pomi-T), where the intake of whole-food supplements rich in polyphenols, showed to reduce the levels of prostate-specific antigen (PSA) and tumour size.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire Healthcare NHS Foundation Trust, Bracknell, UK, and Kevin Johnson, Physical Activity Lead at Macmillan Cancer Support, London, UK, discuss the role of physical activity for people living with and beyond cancer and the rationale for psychological skills training for Physical Activity Specialists to improve the management of psychological distress associated with cancer and cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Does the development of resistant clones in multiple myeloma affect long-term treatment?

To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?

Are there practical considerations for long-term treatment of multiple myeloma?

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University, Oxford, UK, discusses the role of healthcare professionals in addressing cancer patients’ sexuality needs and the role of assessment models, such as BETTER (Bring up sexuality; Explain role of sexuality in quality of life; Tell about and facilitate resources; Timing critical; Educate patient and partner; Record in health record), for raising sexual issues. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Leading researcher Dr. Kanti Rai has devoted his career to understanding and classifying CLL. After Dr. Rais return from the iwCLL conference, Patient Power founder Andrew Schorr visited with Dr. Rai to learn more about progress in CLL biology and how it could positively impact treatment options. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our latest Ask the Expert segment with MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance (SCCA), he answers viewer Verns question, What is the DIPSS scoring system, and how is it used in the monitoring of MPNs? Dr. Scott explains risk scores associated with survival and how that affects choices for treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, and Jasmine Hebden, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, UK, discuss the introduction of new patient-focused initiatives designed to address patients unmet needs at the end of treatment in haemato-oncology, including combining interventions such as holistic-needs assessment and support-events provision. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Debbie Gillen, of The Christie NHS Foundation Trust, Manchester, UK, discusses an acute oncology education campaign that was designed to provide acute oncology education to community and primary care teams, and thereby improve the standards of awareness and support for patients outside of the hospital setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of Northampton General, Hospital NHS Trust, Northampton, UK, discusses a new lung cancer pathway project, which was designed to improve the quality of treatment and care patients receive through approaches that address the individual patient’s needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management needs of men that have survived prostate and testicular cancer for the development of the web-based, self-management programme, iHOPE. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, explains the clinical impact of emerging treatments, including abiraterone acetate and enzalutamide in both post-chemotherapy and pre-chemotherapy settings, on the care and quality of life of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom and beyond, Catherine Oakley, PhD, UKONS President 20142016, and Chemotherapy Nurse Consultant at Guy’s and St Thomas’ NHS Foundation Trust, London, UK, explains the theme of the conference, Patient Safety, and the four subsidiary topics, Haemato-Oncology Nursing, Early Diagnosis and Treatment, Supporting Cancer Nurses and Initiatives in the Treatment and Care of People with Cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that genetic differences between primary and metastatic breast cancer may have important clinical implications, including for the identification of biomarkers for disease progression. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, explains that nutrition has an important role in the treatment of cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported at the European Cancer Congress (ECC) 2015 in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Can MPN patients develop biological markers that influence their current therapies? Yes, says MPN expert Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center. Dr. Verstovsek discusses genetic mutations and drug resistance and what researchers are doing to stay ahead. He remains optimistic for the future as clinical trials continue to indicate increased benefits to the MPN patient population. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How has the field of MPNs expanded in the last 10 years? Meet MPN expert Dr. Laura Michaelis, Clinician and Clinical Researcher at Medical College of Wisconsin. She sat down with Andrew to discuss the evolving landscape of MPNs and new scientific advantages that have her and other researchers excited. Using the analogy of a garden and weeds, Dr. Michaelis walks us through genetic aberrations, JAK-STAT pathway, driver mutations, and precision medicine, ending with the advent of social medias role in accelerating communication in the field of MPNs. Listen as she comments on all this progression as eventually curing people,…

Fresh from the iwCLL, CLL expert Dr. William Plunkett, Professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center shares the latest news on CLL therapeutics with Andrew. Dr. Plunkett is on the cutting edge of biological therapy and speaks confidently of the progression of CLL treatments. Listen as he states, The future is bright for development ofdemonstrably curative CLL therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Can patient care be coordinated regardless of what country you live in? When should an MPN patient start seeking expert care? MPN expert Dr. Bart Scott, Director of Hematology and Hematologic Malignancies at Seattle Cancer Care Alliance, answers these questions. Dr. Scott also discusses when an MPN patient may require changes to their treatment and what those options are, including clinical trials. Listen as Dr. Scott explains why this is a hopeful time for MPN patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Toni Choueiri, MD of the Dana-Farber Cancer Institute welcomes viewers to the 14th International Kidney Cancer Symposium 2015

Toni Choueiri, MD of the Dana-Farber Cancer Institute How Does the Axitinib Plus Pembrolizumab study impact future research?

Toni Choueiri, MD of the Dana-Farber Cancer Institute discusses the Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses the next steps Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer what are the next steps?

Michael Bassetti MD PhD of University of Wisconsin Madison discusses What’s the Impact to Physicians Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer an Overview

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP. For more information, visit http://www.cancertypeid.com

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the impact of the Oncotype DX® Breast Cancer Assay, a multigene assay that stratifies patients into risk groups that are associated with distant recurrence and response to adjuvant chemotherapy, on treatment decisions for patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa, a prospective, global observational study that was designed to describe patterns of care and outcomes for men with late-stage prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology-organised multidisciplinary Task Force, which focuses on reviewing access to innovation in all fields of oncology. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, reviews the predictive and prognostic value of currently available multigene assays for the management of patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The Oncotype DX® Breast Cancer Assay, a multigene assay, stratifies breast cancer patients into groups that are at low, intermediate or high risk for distant recurrence and guides decision making for adjuvant chemotherapy. At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, explains the factors that were associated with the implementation of the Oncotype DX assay in different healthcare systems. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial, which evaluated erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Enriqueta Felip – Targeted therapies in ALK-positive NSCLC

@OncEd Presents Dr. Simon Raphael – Actionable biomarkers in NSCLC: EGFR and ALK

@OncEd Presents Dr. Keith Flaherty – Integrating new treatment options for melanoma

@OncEd Presents Dr. Keith Flaherty – An expert’s perspective on frequently asked questions on BRAF V600-mutated advanced melanoma

@OncEd Presents – Dr. Natasha Leighl & Dr. David Hogg – Immune Response Vs. RECIST Criteria

@OncEd Presents Dr. Lori Wood – Optimizing Outcomes in Advanced Prostate Cancer

Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis, to improve the outcomes of cancer patients.

Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference covers the whole range of cancer research from prevention and early diagnosis through basic science, translational science, clinical research, survivorship and palliative care research. Karen Kennedy also discusses recent NCRI initiatives on pathology research, and long-standing initiatives on radiotherapy and survivorship.

Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he explains what is epigenetics, it’s role in cancer cells and the importance of developing novel cancer treatments that inhibit the regulation of this mechanism.

Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that resulted from the combination of Breakthrough Breast Cancer and Breast Cancer Campaign. The charity has set the goal to prevent breast cancer death by 2050, which will be achieved by continuing to provide funding to breast cancer treatment, but also focusing on prevention, policies and economics in breast cancer.

Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he described a new technique called nuclear spin hyperpolarization, that can increase the sensitivity of the magnetic resonance by 10,000 fold. This technique can have several uses, including detection of treatment response and investigation of tumour microenvironment. In his talk Kevin Brindle focuses on the use of this technique in brain tumours.

Harpal Kumar, MA MEng MBA DSc gives an overview of his session at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he discusses the efforts of the National Awareness and Early Diagnosis Initiative (NAEDI) to develop a better understanding of the contribution of late diagnosis to the UK’s relatively poor cancer survival rates and develop strategies to address this.

Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, that focuses on the importance of providing GPs and oncologists with a tool that can help them systematically assess the patient and carer needs. These needs can range from physical and psychological symptoms to legal, financial and work related matters that could directly affect the quality of life and cancer patients and their carers. The session hosted talk by Irene Higginson, Wei Gao and Christina Remsenthaler.

With the advent of unlocking genetic code, the cancer community has now been introduced to the concept of immunotherapy. What does this mean specifically for MPN patients? For MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center, genetics hold many answers but add a level of complexity related to prognosis and treatment. Dr. Mark Heaney of Columbia University Cancer Center views genetics in terms of interpreting how aggressive the disease may be, while Bob Rosen, patient advocate and Chairman of MPN Research Foundation, suggests that patients put the role of genetics into perspective by connecting with a specialist. Get…

In this segment of The Conversation, MPN Edition, Dr. Srdan Verstovsek of MD Anderson Cancer Center, MPN expert Dr. Mark Heaney of Columbia University Cancer Center, and Bob Rosen, Chair of MPN Research Foundation share their insight and views on clinical trial participation. Listen closely as the guests discuss the differences between the REVEAL study and the PEGASYS trial, highlighting the outcomes, reasons, and options for both participation and non-participation in clinical trials and observational studies. As Bob Rosen says, it’s a “balancing act for patients and their doctors to decide.” Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube |…

CLL patients with certain genetic markers are considered to be high risk and their options for treatment have historically been limited. CLL expert Dr. Jeff Sharman joins Patient Power to discuss emerging approaches to treating high-risk CLL currently being studied in clinical trials. Sponsored through an educational grant from TG Therapeutics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

MPN experts Dr. Mark Heaney of Columbia University Cancer Center and Dr. Srdan Verstovek of MD Anderson Cancer Center examine the expanding polycythemia vera (PV) armamentarium, answering the question, “Where are we now?” Dr. Heaney discusses second generation inhibitors and customization of treatment, while Dr. Verstovek focuses on combination therapies and expanded options coming from interferon trials in Europe. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating, a leading researcher from MD Anderson Cancer Center, has had a career that spans decades and has witnessed the evolution of CLL research. Andrew Schorr, the founder of Patient Power, sat down with Dr. Keating to discuss promising developments in CLL research and Dr. Keatings ongoing commitment: to stay alive until CLL is cured. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. In his talk he discusses how the burden of cancer can be reduced by dietary modifications. Prof. Boffetta also highlights the importance of having a healthy and balanced diet, which includes fruit, vegetables and protein, and to try and avoid focusing on one specific food item or chemical element.

Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, focusing on molecular testing for early cancer diagnosis. The session included talks by Marc Tischkowitz and Peter Sasieni. Marc Tischkowitz focused on tests for genetic predisposition of ovarian cancer and results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study, whilst Peter Sasieni addressed the bigger question about biomarkers and how they are useful at different stages of early detection. Rebecca Fitzgerald also introduces Cytosponge, a non-endoscopic cell collection tool that in combination with oesophageal biomarkers can aid…

Chad Creighton of the Baylor College of Medicine: “How does the Papillary RCC: The Cancer Genome Atlas (TCGA) impact Physicians?”

Chad Creighton of Baylor College of Medicine discusses the next steps for Papillary RCC: The Cancer Genome Atlas (TCGA)

Chad Creighton of Baylor College of Medicine discusses a short overview of the Papillary RCC: The Cancer Genome Atlas (TCGA)

Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse and Leland Hartwell, that would eventually lead to the award of a Nobel Prize in Physiology or Medicine in 2001.

Jack Cuzick, PhD, FMedSci, FRCP(hon), of the Queen Mary University of London, UK gives an overview of the session ‘Prevention is better than cure’ cancer chemoprevention in 2015, presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. The session included speakers such as Andrew Chan, Sam Behjati, Dario Alessi and Henry Kitchener.

In the session ” Tumour: stroma interactions” presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, the importance of stromal interaction in the tumour environment is discussed by Kairbaan Hodivala-Dilke, Ilirjana Bajrami, Helmut G. Augustin, Jason Fleming and host Erik Sahai. Whilst it has been realised for many years that cancer is a process driven by mutations within the cells, it is also clear now that those cells also have complicated interactions with neighbouring cells and the local environment. The focus of this session was to try to understand how the complex interactions between tumour cells and stroma…

Clare Turnbull, MD, PhD, gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where the Genomics England clinical interpretation partnership (GeCIP) was presented. In her talk, Dr Turnbull described how the programme plans to sequence the whole genome of thousands of cancer patients recruited within the NHS. This will generate enormous data and sample resources that will be made searchable through GeCIP.

Neeraj Agarwal, MD of the Huntsman Cancer Institute presents “Molecular predictors of response and survival outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with VEGF-TKIs” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine presents “Development of an Antibody-free Method for Detecting Renal Cell Carcinoma Circulating Tumor Cells” at the 14th International Kidney Cancer Symposium.

David Gill, MD of the Huntsman Cancer Institute presents “Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in metastatic clear cell renal cell carcinoma (mccRCC).” at the 14th International Kidney Cancer Symposium.

Peter F. Thall, PhD of M.D. Anderson Cancer Center presents “Bayesian Designs for Early Phase Clinical Trials” at the 14th International Kidney Cancer Symposium.

Meredith M. Regan, ScD of the Dana-Farber Cancer Institute presents “Statistical Considerations in RCC: Biomarker-Based Studies” at the 14th International Kidney Cancer Symposium.

Wayne A. Marasco, MD, Ph.D.of the Dana-Farber Cancer Institute presents “Carbonic Anhydrdase IX: Opportunities for Immune-Based Approaches” at the 14th International Kidney Cancer Symposium

Daniel Lindner, MD, PhD of the Cleveland Clinic presents “Patient derived xenograft models and ? potential therapeutic applications” at the 14th International Kidney Cancer Symposium.

Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “The Evolving Role of Chromatin and Epigenetics in RCC” at the 14th International Kidney Cancer Symposium.

Sumanta Kumar Pal, M.D. of the City of Hope Comprehensive Cancer Center presents “Applying Advanced Genomics to Therapy Selection” at the 14th International Kidney Cancer Symposium.

Brian Rini, MD of the Cleveland Clinic presents “2015 Eugene P. Schonfeld Award” at the 14th International Kidney Cancer Symposium.

Eliezer (Eli) Van Allen, MD of Dana-Farber Cancer Institute presents “Expanding the clinically actionable kidney cancer genome” at the 14th International Kidney Cancer Symposium.

Brian R. Lane, M.D., Ph.D., FACS of Spectrum Health Medical Group? presents “Molecular Prediction of Kidney Cancer Recurrence”

Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “KCA Role in Developing a Research Program in Kidney Cancer Epigenetics” at the 14th International Kidney Cancer Symposium.

André P. Fay, MD of Dana-Farbe presents “Treatment of Kidney Cancer in Developing Countries ” at the 14th International Kidney Cancer Symposium

Thomas E Hutson, DO, PharmD, FACP of the Baylor-Sammons Cancer Center presents “Emerging Targeted Therapies” at the 14th International Kidney Cancer Symposium.

Laurence Albiges presents “Emerging Biomarkers of VEGF and mTOR Inhibitors in 2015” at the 14th International Kidney Cancer Symposium.

Daniel Y C Heng MD MPH FRCPC of the University of Calgary presents “Improving Patient Care Through Health Outcome Research in RCC” at the 14th International Kidney Cancer Symposium.

Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how lifestyle changes, such as physical activity and diet, can reduce the risk of progression of prostate cancer.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is implementing to increase conversations about physical activity between healthcare professionals and cancer patients.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer Support initiative aimed at helping cancer patients integrate physical activity into their routine.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses the results to date for Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial evaluating the utility of the Oncotype DX® Breast Cancer Assay to guide adjuvant treatment decisions in patients with ER-positive, HER2-negative, node-negative breast cancer. Promising outcomes at 5 years were reported in patients with a low Oncotype DX Recurrence Score® (RS) result, which suggests this population may be safely spared of chemotherapy. The evaluation continues in the study group comprising…

Judge Schonfeld-CEO-CureHunter Inc. presents “Speeding Drug Discovery with Computational Biology Network Graph Theory” at the 14th International Kidney Cancer Symposium.

John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.

Jeffrey Wallin, Ph.D. of Genentech presents “Opening the Floodgates to T Cells Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC” at the 14th International Kidney Cancer Symposium.

Fabian Zohren, MD PhD from Takeda presents “Inhibiting the mTOR Complex: Biology and Targets” at the 14th International Kidney Cancer Symposium.

Mark W Ball presents “Pathologic and Genomic Profiles of Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Toni Choueiri, MD Dana-Farber Cancer Institute presents “Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Michael Postow, MD from Memorial Sloan Kettering Cancer Center presents “Managing Side Effects of Immune Checkpoint Blockade” at the 14th International Kidney Cancer Symposium .

Dan George, MD Duke Cancer Institute presents “Oncolytic Viruses” at the 14th International Kidney Cancer Symposium.

David McDermott, MD of Dana Farber presents “The Really Important Questions Current Immunotherapy Trials are Not Answering” at the 14th International Kidney Cancer Symposium.

Ronit Simantov, M.D. of Pfizer Oncology presents “Optimizing Therapy of RCC through Industry-Academic Collaborations” at the 14th International Kidney Cancer Symposium.

Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents “Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial” at the 14th International Kidney Cancer Symposium.

Hans Hammers MD, PhD of Johns Hopkins presents “Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors” at the 14th International Kidney Cancer Symposium.

Charles G. Drake MD of Johns Hopkins Kimmel Cancer Center presents Combination Immunotherapeutic Strategies in RCC: Preclinical Rationale AND Clinical Experience

Gordon Freeman, PhD from the Dana-Farber Cancer Institute Harvard Medical School presents “The Biology of Checkpoint Inhibition” at the 14th International Kidney Cancer Symposium.

Moshe C. Ornstein MD MA of the Cleveland Clinic Taussig Cancer Institute presents “Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Andrew J. Armstrong MD ScM FACP of Duke Cancer Institute presents “Clinical Trials in Non-Clear Cell RCC” at the 14th International Kidney Cancer Symposium.

Jose A. Karam, MD, FACS of MD Anderson presents “RCC with Sarcomatoid Dedifferentiation: New Insights” at the 14th International Kidney Cancer Symposium.

Gabriel G. Malouf, MD, PhD of Pitie Salpetriere Hospital presents “Collecting Duct Renal Cell Carcinomas” at the 14th International Kidney Cancer Symposium.

Chad Creighton of Baylor College of Medicine presents “Papillary RCC: The Cancer Genome Atlas (TCGA)” at the 14th International Kidney Cancer Symposium.

Payal Kapur, M.D. of UT Southwestern Medical Center presents “Chromophobe Renal Cell Carcinoma: TCGA and UTSW Updates’ at the 14th International Kidney Cancer Symposium.

Eric Jonasch Professor of Medicine UT MD Anderson Cancer Center presents “VHL Syndrome and Hemangioblastoma Management” at the 14th International Kidney Cancer Symposium.

Paul Russo, MD, FACS of Cornell University presents “Partial Nephrectomy 15 YEARS OF PROGRESS” at the 14th International Kidney Cancer Symposium.

Suzanne B. Stewart-Merrill. MD presents ” Oncologic Surveillance Following Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach” at the 14th International Kidney Cancer Symposium.

Michael L. Blute Jr,. MD of the University of Wisconsin presents “Novel 3D volume analysis reveals primary tumor diameter is a poor predictor of tumor volume; does tumor burden actually predict survival after cytoreductive nephrectomy?’ at the 14th International Kidney Cancer Symposium.

Sarah P. Psutka M.D., M.Sc of Cook County, Chicago presents “Management of Local Recurrence After Radical Nephrectomy” at the 14th International Kidney Cancer Symposium.

E. Jason Abel, M.D. of the University of Wisconsin presents “Patient Selection for Surgery in RCC with Thrombus” at the 14th International Kidney Cancer Symposium.

Dipen J. Parekh, MD of the University of Miami Miller School of Medicine presents “WARMING UP TO ISCHEMIA” at the 14th International Kidney Cancer Symposium

Karim Touijer , MD, MPH from the Memorial Sloan-Kettering Cancer Center presents “Partial Nephrectomy: Does Ischemia Matter?” at the 14th International Kidney Cancer Symposium

James Porter of the Swedish Medical Center Seattle, WA presents “Minimally Invasive Lymphadenectomy for Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Steven C. Campbell, MD, PhD of The Cleveland Clinic discusses “Optimal Treatment of cT1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine discusses “Novel Imaging Techniques in RCC” at the 14th International Kidney Cancer Symposium.

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses “University of Wisconsin Madison” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

R. Houston Thompson, MD Professor of Urology Mayo Clinic discusses “Partial Nephrectomy or Ablation for Small Renal Mass” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Michael A.S. Jewett discusses “Surveillance is the Best Treatment for T1a RCC in a healthy 65 year old patient” at the Fourteenth International Kidney Cancer Symposium Miami, Florida, USA, November 6th , 2015 www.kidneycancersymposium.com

Stephen A. Boorjian, MD of the Mayo Clinic, Rochester, MN discusses ” CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Bradley C. Leibovich, MD, FACS , Mayo Clinic debates ” Renal Mass Biopsy Should Be Used Sparingly in patients with SRM” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Tony Finelli, MD, MSc, FRCSC Head, Division of Urology GU Site Lead, Princess Margaret Cancer Center debates the Pro side to “Renal Mass Biopsy Should be Used for Most SRM – PRO” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

A Ari Hakimi MD Memorial Sloan Kettering Cancer Center brings an “Update on Molecular and Genetic Characterization of RCC” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Brian R. Lane, M.D., Associate Professor, Michigan State University discusses “Improving Healthcare Delivery in Kidney Cancer” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the Bedford Hospital, Bedford, UK. The results of this study were presented at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma. This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.       update, update checkmate 067, phase 3 study, nivolumab, nivolumab plus ipilimumab, ipilimumab alone, in previously untreated advanced melanoma, advanced melanoma, ncri 2015, ncri, national cancer research institute, cancer conference

Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity the panacea?” at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Prof. Rob Coleman gives an overview of the session “This house believes we should stop focussing on the causes of breast cancer and get on with strategies to prevent the disease”, presented at the 2015 NCRI Cancer Conference. With Douglas Easton and Tim Key supporting the causes side, and Annie Anderson and Gareth Evans supporting the prevention side. The session was hosted by Prof. Rob Coleman.

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered by scientists from the Francis Crick Institute at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include Tim Hunt, Richard Treisman, Nicholas Luscombe, Erik Sahai and Adrian Hayday. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the featured sessions of the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include sessions by Alberto Bardelli, Thierry Voet, Erik Sahai, Adrian Hayday, James Larkin, Sergio Quezada, Robert Peston and Fabrice André. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the 2015 National Cancer Research Institute (NCRI) Cancer Conference, which will focus on integrating basic, translational and clinical cancer research, and cover topics such as cancer evolution, single cell genomics, cancer immunology, cancer cell cycle and health economics in cancer. Key speakers and hosts include Thierry Voet, Alberto Bardelli, Adrian Hayday, Sergio Quezada, Tim Hunt, Denis Slamon and Robert Peston. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing that in reality each patient responds differently, Dr. Naughton stresses the importance of tailoring treatment decisions based on the individual patient situation. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses Trial Assigning IndividuaLized Options for Treatment (TAILORx), a prospective phase 3 clinical trial that was designed to evaluate the utility of the Oncotype DX® Breast Cancer Assay to risk stratify patients with oestrogen receptor-positive, HER2-negative, node-negative breast cancer. By identifying low-risk patients who are unlikely to benefit from adjuvant chemotherapy, the test may allow physicians to direct patients to individualised therapies that are associated with improved health outcomes. This content is supported by Genomic Health, Inc. European Medical Journal…

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-centre, multi-arm, randomised phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to weigh patient benefit versus the impact on quality of life due to these side effects and safety risks when considering patient treatment options. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, outlines potential therapeutic applications, including immune and adaptive approaches, of an improved understanding of cancer genes and mutational processes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient Reported Opinions about Clinical Tolerability (PROACT), a mobile platform designed to enable patients to directly contribute to the understanding of investigational agents in early clinical development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, discusses a European Registration of Cancer Care (EURECCA) international comparison of treatment patterns for patients aged 70 years and older with non-metastatic breast cancer in four European countries. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Nancy Zhu – Case-Based Discussion for Managing MDS Patients. This live webinar took place on September 10, 2015.

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, explains that anti-tumour immunity has the potential to be exploited clinically against the evolutionary process that drives cancer development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, a study of the molecular epidemiology of resected stage I-III non-small cell lung cancer (NSCLC) tumours and association with clinicopathological features and outcomes in patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Martin Reck – ECC 2015 Immunotherapy Updates

@OncEd Presents Dr Luis Bruno – ECC 2015 GU Cancer Highlights (Portuguese Version)

@OncEd Presents Dr. Stephanie Snow – ECC 2015 Head and Neck Updates

@OncEd Presents Dr. Scott Berry – ICECREAM Trial

@OncED Presents Dr. Scott Berry – COMET Trial

@OncEd Presents Dr. Nadia Harbeck – PALOMA 3 Trial

@OncEd Presents Dr. Ralph Wong – Neuroendocrine Tumour Updates

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter

@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study

@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC

@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention

@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates

@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors

@OncEd Presents Dr. Stephen Doral Stefani – Access and Equity

@OncEd Presents Dr. Wolfgang Janni – DETECT Study

@OncEd Presents Dr. Jean Fayette – UNICANCER Trial

@OncEd Presents Dr Michael Untch – GEPARQUINTO Study

@OncEd Presents Dr. Fernando Rivera – PEAK Trial

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queens University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College London, London, UK, and Francesco de Lorenzo, MD, of European Cancer Patient Coalition (ECPC), Brussels, Belgium, discuss the ECPC initiative, Europe of Disparities in Cancer, which was designed to evaluate the position of European cancer patients on the increasing inequalities in cancer care in Europe. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to determine the optimal adjuvant therapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, discusses prognostic and predictive biomarkers that are enabling more individualised therapies to be applied in molecularly defined breast cancer subgroups. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews